Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.10
+0.9%
$7.04
$3.54
$8.25
$165.43M0.889,338 shs84,240 shs
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$4.62
+0.2%
$5.02
$3.51
$16.95
$39.92M0.2476,474 shs36,005 shs
NextCure, Inc. stock logo
NXTC
NextCure
$0.44
+2.0%
$0.48
$0.22
$1.82
$12.26M1.06126,327 shs85,869 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$27.99
+0.2%
$23.20
$16.16
$28.47
$1.13B0.75213,430 shs322,477 shs
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$3.65
$3.65
$2.41
$6.65
$381.02M0.93.61 million shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Journey Medical Corporation stock logo
DERM
Journey Medical
+1.00%+1.00%-9.86%+6.83%+34.35%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
+5.73%+2.67%+11.89%+19.43%-61.58%
NextCure, Inc. stock logo
NXTC
NextCure
-1.77%-8.11%-10.83%+7.88%-71.45%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+4.96%+12.89%+13.67%+38.18%+67.31%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
0.00%0.00%0.00%0.00%+50.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Journey Medical Corporation stock logo
DERM
Journey Medical
1.6615 of 5 stars
3.51.00.00.00.61.70.6
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.8578 of 5 stars
3.51.00.04.60.62.50.6
NextCure, Inc. stock logo
NXTC
NextCure
4.4055 of 5 stars
3.53.00.04.31.91.71.3
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.5731 of 5 stars
0.82.02.51.12.43.32.5
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.7432 of 5 stars
3.10.00.04.70.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Journey Medical Corporation stock logo
DERM
Journey Medical
3.00
Buy$9.5033.80% Upside
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.00
Buy$43.20835.06% Upside
NextCure, Inc. stock logo
NXTC
NextCure
3.00
Buy$3.50700.92% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.67
Reduce$21.80-22.12% Downside
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
2.13
Hold$8.45131.51% Upside

Current Analyst Ratings Breakdown

Latest KPTI, NXTC, DERM, RVNC, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
5/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.00
5/8/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
4/15/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M2.95N/AN/A$0.91 per share7.80
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$145.24M0.27N/AN/A($22.10) per share-0.21
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$2.34 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.11$2.22 per share12.59$6.34 per share4.41
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
$234.04M1.63N/AN/A($1.73) per share-2.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$76.42M-$13.26N/AN/AN/A-43.99%N/A-35.95%8/5/2025 (Estimated)
NextCure, Inc. stock logo
NXTC
NextCure
-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7835.8913.330.452.68%30.51%6.89%8/27/2025 (Estimated)
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)

Latest KPTI, NXTC, DERM, RVNC, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million
5/12/2025Q1 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/1/2025Q1 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.40-$0.39+$0.01-$0.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.71%N/A61.54%N/A
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/AN/AN/AN/AN/A

Latest KPTI, NXTC, DERM, RVNC, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Journey Medical Corporation stock logo
DERM
Journey Medical
1.07
1.34
1.03
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
1.33
1.28
NextCure, Inc. stock logo
NXTC
NextCure
N/A
10.26
10.26
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
N/A
4.12
3.05

Institutional Ownership

CompanyInstitutional Ownership
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
97.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3808.64 million8.38 millionOptionable
NextCure, Inc. stock logo
NXTC
NextCure
9028.05 million23.03 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Revance Therapeutics, Inc. stock logo
RVNC
Revance Therapeutics
500104.39 million99.07 millionOptionable

Recent News About These Companies

Crown Laboratories Now Operates Under the Name Revance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.10 +0.06 (+0.85%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$4.62 +0.01 (+0.22%)
As of 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

NextCure stock logo

NextCure NASDAQ:NXTC

$0.44 +0.01 (+2.03%)
As of 02:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$27.99 +0.05 (+0.18%)
As of 03:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Revance Therapeutics stock logo

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)
As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.